IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: **LOSCALZO et al**

Application No.: **NOT YET ASSIGNED**

Filed: **October 7, 2003**

For: **Methods of Treating Vascular Diseases Characterized by Nitric Oxide Insufficiency**

Attorney Docket No.: **102258.337US2**

MAIL STOP PATENT APPLICATION
Commissioner of Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449 form.

The submission of this Information Disclosure Statement does not represent that a search has been made and does not constitute an admission that the listed documents are material to patentability or that the listed documents are prior art.

The documents listed on the attached PTO-1449 Form are not being submitted herewith since they were previously submitted in parent Application No. 09/697,317, to which the present application claims priority. 37 CFR § 1.98(d).

This Information Disclosure Statement is being submitted concurrently with the application. Accordingly, no fee is due.

Applicants respectfully request that the Examiner initial and return a copy of the enclosed PTO-1449 form with the next communication from the Patent Office.

Respectfully submitted,

Edward D. Grieff
Registration No. 38,898

Date: October 7, 2003
HALE AND DORR LLP
1455 Pennsylvania Avenue, NW
Washington, DC 20004
Phone: (202) 942-8400

Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

Complete if Known	
Application Number	
Filing Date	
First Named Inventor	Loscalzo
Group Art Unit	
Examiner Name	
Attorney Docket Number	102258.337 US2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		4,868,179		Cohn	09-19-1989	
		5,645,839		Chobanian et al	07-08-1997	
		5,891,459		Cooke et al	04-06-1999	
		5,968,983		Kaesemeyer et al	10-19-1999	
		5,973,011		Noack et al	10-26-1999	
		6,103,769		Kelm	08-15-2000	
		6,117,872		Maxwell et al	09-12-2000	
		5,627,191		Birch et al	05-06-1997	
		6,319,515	B1	Hidaka et al	11-20-2001	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		WO	95/26725		Noack et al	10-12-1995		
		WO	99/66921		Cooke et al	12-29-1999		
		WO	98/21193		Del Soldato	05-22-1998		
		WO	99/00361		Del Soldato	01-07-1999		
		WO	99/67231		Del Soldato	12-29-1999		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → [+]

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Complete if Known	
Application Number	
Filing Date	October 27, 2000
First Named Inventor	Loscalzo
Group Art Unit	
Examiner Name	
Attorney Docket Number	102258.337US1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		Cohn et al, The New England Journal of Medicine, 325(5):303-310 (1991).	
		Cohn et al, The New England Journal of Medicine, 314(24):1547-1552 (1986).	
		Carson et al, Circulation, Supplement I, 92(8):I31-I32, Abstract No. 0145 (1995).	
		Francis et al, Circulation, Supplement VI, 87(6):VI40-VI48 (1993).	
		Pierpont et al, Chest, 73(1):8-13 (1978).	
		Massie et al, The American Journal of Cardiology, 40:794-801 (1977).	
		Kaplan et al, Annals of Internal Medicine, 84:639-645 (1976).	
		Bauer et al, Circulation, 84(1):35-39 (1991).	
		The SOLVD Investigators, The New England Journal of Medicine, 327(10):685-691 (1992).	
		Ziesche et al, Circulation, 87(6):VI56-VI64 (1993).	
		Rector et al, Circulation, 87(6):VI71-VI77 (1993).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → [+]

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

Complete if Known	
Application Number	
Filing Date	October 27, 2000
First Named Inventor	Loscalzo
Group Art Unit	
Examiner Name	
Attorney Docket Number	102258.337US1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		Carson et al, Journal of Cardiac Failure, 5(3):178-187 (September 10, 1999).	
		Dries et al, The New England Journal of Medicine, 340(8):609-616 (February 25, 1999).	
		Freedman et al, Drugs, 54(Supp. 3):41-50 (1997).	
		Sherman et al, Cardiologia, 42(2):177-187 (1997).	
		Biegelson et al, Coronary Artery Disease, 10:241-256 (1999).	
		Rudd et al, Am. J. Physiol., 277(46):H732-H739 (1999).	
		Hammerman et al, Am. J. Physiol., 277(46):H1579-H1592 (1999).	
		Loscalzo et al, Transactions of the American and Climatological Ass., 111:158-163 (2000).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → [+]

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 4

Complete if Known	
Application Number	
Filing Date	
First Named Inventor	Loscalzo
Group Art Unit	
Examiner Name	
Attorney Docket Number	102258.337 US2

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		Dupuis, Cardiovascular Drugs and Therapy, 8(3):501-507 (1994).	
		Dupuis, Cardiovascular Drugs and Therapy, 8(3):501-507 (1994) (ABSTRACT).	
		von Lutterotti et al, American Journal of Hypertension, 4(4 Part 2):346S-349S (1991).	
		Burnier et al, Hypertension, 22(3):339-347 (1993).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.